As an important part of the bio-industry sector, the development momentum of the in vitro diagnostic (IVD-In Vitro Diagnostics) industry has been very rapid in recent years. According to statistics, in 2008, the global in vitro diagnostic market reached 38.42 billion US dollars. According to professional estimates, from 2010 to 2012, the global IVD market will still maintain a growth rate of around 9%.

With the promulgation of the "Decision of the State Council on Accelerating the Cultivation and Development of Strategic Emerging Industries" last year, it will inject a strong boost to the country's rapidly growing bio-industry, which will greatly promote the growth rate of China's biotechnology companies.

Insiders pointed out: "After the introduction of this policy, the domestic bio-industry will gradually narrow the gap with its international counterparts. This will not only help China to develop brand-name companies with independent intellectual property rights, but also allow investors to see a new investment direction."

As an important component of the bio-industry sector, the development momentum of the in vitro diagnostics (IVD) industry is also very rapid. With the development of the biotechnology industry in the future, China's IVD will usher in the golden period of development.

Biochemical reagents have great potential

According to professional estimates, from 2010 to 2012, the global IVD market will still maintain a growth rate of around 9%. At present, China is the fastest growing country in the IVD market with an average annual growth rate of 15% to 20%.

According to statistics, the market size of in vitro diagnostics in China reached 9.3 billion yuan in 2008, and the per capita annual expenditure was 6.64 yuan, while the per capita annual expenditure in Japan in 2008 was 227.5 yuan. It can be said that China's IVD industry has just entered the spring.

According to statistics, about 80% of clinical diagnostic information comes from in vitro diagnostics, and its cost accounts for less than 20% of medical expenses. In vitro diagnosis has become an increasingly important part of human disease prevention, diagnosis, and treatment, and it is an increasingly important component of safeguarding human health and building a harmonious society.

In recent years, the rise and integration of various new technologies and methods have promoted the development, application, and replacement of in vitro diagnostic reagents. At present, China's in-vitro diagnostic reagent market is mainly composed of the following parts: The largest amount of immunological diagnostic reagents, the market share of 33%, followed by clinical biochemistry 26%, blood analysis 12%, molecular detection 4%, blood coagulation 4% Urine testing was 4%, critically ill patients were 4% chemical, and the other 13%.

Experts said that while the scale of immunological reagents is gradually expanding, as a basic component of medical tests, clinical biochemical reagents still retain a large market share due to their advantages of low cost and high speed, and for a very long time Difficult to be replaced. With the popularity of automatic biochemical analyzers in county-level hospitals and semi-automatic biochemical analyzers in primary hospitals, it is expected that in the next few years, China's biochemical reagents market will exhibit high-speed growth that exceeds the average growth rate of the industry. According to professional analysis, in 2009 the scale of China's biochemical reagent market reached 2.6 billion yuan, and by 2013 China's biochemical reagent market will reach 5.9 billion yuan.

Big Three

As a vital market for the development of the global in vitro diagnostics industry, China has continuously emerged in recent years as a market-competitive indigenous in-vitro diagnostic company. In the national chemical reagent market, Sinon, Kehua Bio, and Leadman ranked the top three in market share.

At present, among these companies, China Health North Control and Kehua Bio are listed. Under the dual benefits of industry development and national policies, they are favored by many investors. With its success in the capital market, Kehua Biotech has strengthened its layout in the field of biochemical reagents. In March 2010, Kehua Biotechnology purchased Kehua Dongling, and tried to double the income of biochemical reagents by virtue of the accumulation of biochemical reagents in Donghualing. Experts expect that the growth rate of biochemical biochemical reagents will exceed 30% in the next few years. Some unlisted indigenous in-vitro diagnostic companies such as Lidman, in the context of industry development, have seen rapid growth in scale and effectiveness, and biochemical diagnostic reagent product varieties and product quality have been greatly improved.

At present, leading companies in the industry have adopted product diversification strategies to enter biochemical reagents, chemiluminescent immunoassays, and molecular diagnostics. Kehua Bioscience also announced that it will focus on diversification-related diversification strategies and focus on the development of chemiluminescence, nucleic acid, and other aspects in diagnostic reagents. In addition to Kehua Bio, the product lines of many domestic leading companies such as Fuxing, Wantai, Leadman, Jinhao, Rongsheng, Xinchuang, Huamei, etc. have also become more and more abundant. While doing a good job in the main industry, Product diversification is actively oriented to conform to the development trend of the diagnostic industry.